|
Press Releases |
|
|
|
Thursday, July 20, 2023 |
|
エーザイ、「レカネマブ」について、アルツハイマー病の病理に対する効果、および皮下投与に関する最新の解析結果をアルツハイマー病協会国際会議2023(AAIC2023)において発表 |
エーザイ株式会社とバイオジェン・インクは、このたび、アルツハイマー病(AD)治療剤レカネマブ(一般名、米国ブランド名:「LEQEMBI」)について、臨床第III相Clarity AD試験におけるレカネマブ投与によるアミロイドベータ(Aβ)の減少とパスウェイにおける下流のバイオマーカー変化の解析結果、ならびに現在開発中の皮下投与製剤に関する最新知見をアルツハイマー病協会国際会議2023において、発表したことをお知らせします。 more info >> |
|
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023 |
Eisai Co., Ltd. and Biogen Inc. announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb (generic name, U.S. brand name: LEQEMBI) treatment showed reductions in amyloid-beta (Abeta) pathology and downstream biomarker changes. more info >> |
|
Wednesday, July 12, 2023 |
|
Eisai to Present the Latest Alzheimer's Disease Pipeline and Research |
Eisai Co. Ltd announced today that the company will present the latest findings on its Alzheimer's disease (AD) pipeline and research, including Eisai's anti-amyloid beta (Abeta) protofibril* antibody for the treatment of Alzheimer's disease (AD). more info >> |
|
Friday, July 7, 2023 |
|
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI more info >> |
|
エーザイとバイオジェン・インク、「LEQEMBI(R)」(レカネマブ)がアルツハイマー病治療薬として米国FDAよりフル承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)とバイオジェン・インク(Nasdaq:BIIB、本社:米国マサチューセッツ州ケンブリッジ、CEO:Christopher A. Viehbacher、以下 バイオジェン)は、このたび、米国食品医薬品局(FDA)が「LEQEMBI(R)」注射100 mg/mL溶液(一般名:レカネマブ)について、フル承認に向けた生物製剤承認一部変更申請(supplemental Biologics License Application:sBLA)を承認したことをお知らせします。 more info >> |
|
Friday, June 30, 2023 |
|
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced |
Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement. more info >> |
|
Thursday, June 29, 2023 |
|
エーザイ、Gates Ventures、Health Data Research UK、LifeArc、およびエジンバラ大学は認知症の課題解決に寄与するデジタル・ソリューション開発をめざす共同研究「NEURii」を開始 |
エーザイ株式会社(本社:東京都)、Gates Ventures(米国、シアトル)、Health Data Research UK(英国、ロンドン、以下、HDR UK)、LifeArc(英国、ロンドン)、およびエジンバラ大学(英国、エジンバラ)は、このたび、2年間の新規共同研究契約を締結したことをお知らせします。 more info >> |
|
Thursday, June 22, 2023 |
|
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City |
Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NOH"), Eisai's digital tool for self-assessment of cognitive function, will continue to be promoted as part of the FY2023 dementia examination project, conducted by Bunkyo City, Tokyo. more info >> |
|
エーザイ、東京都文京区の2023年度認知症検診事業において「のうKNOW(R)」による脳の健康度測定を継続実施 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、このたび、東京都文京区(以下、文京区)が実施する2023年度認知症検診事業(以下、本事業)において、当社の認知機能のデジタルチェックツール「のうKNOW(R)」による脳の健康度測定が継続実施されることをお知らせします。 more info >> |
|
Monday, June 12, 2023 |
|
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai's Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use for the treatment of Alzheimer's disease (AD). more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
PAREMINAが革新的な抗老化ソリューションを携えて、Beautyworld Tokyo 2024でアジア初上陸を発表
Apr 18, 2024 13:45: JST
|
|
|
To acquire stake in Hangzhou Bizike, Phoenitron Holdings has eye on trillion-dollar e-commerce market
Apr 18, 2024 11:51 HKT/SGT
|
|
|
The Executive Centre Announces Record Revenue in FY2023 Annual Results
Apr 18, 2024 11:00: JST
|
|
|
富士通とオラクル、日本市場におけるデータ主権要件に対応するソブリンクラウドの提供に向け戦略的協業
Apr 18, 2024 11:00: JST
|
|
|
Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan
Apr 18, 2024 11:14 JST
|
|
|
德事宣布2023年收入创新高
Apr 18, 2024 10:02 HKT/SGT
|
|
|
德事商務中心(TEC)2023年收入創新高
Apr 18, 2024 10:01 HKT/SGT
|
|
|
The Executive Centre Announces Record Revenue in FY2023 Annual Results
Apr 18, 2024 10:00 HKT/SGT
|
|
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Apr 18, 2024 10:53 JST
|
|
|
All-New Triton Confirmed as First Double-Cab Pickup Truck to Achieve 2024 Five-Star ANCAP Safety Rating
Apr 18, 2024 9:22 JST
|
|
|
The Rapidly Evolving Real Estate Landscape: Redefine Real Estate Summit Connects Key Players in South East Asia
Apr 18, 2024 08:11 HKT/SGT
|
|
|
Prestigious titles for top developers at the 14th PropertyGuru Asia Property Awards (Singapore)
Apr 18, 2024 08:00 HKT/SGT
|
|
|
Eesee Implements Blockpass for Compliance in Digital Assets Marketplace
Apr 18, 2024 07:00 HKT/SGT
|
|
|
PaySaxas啟動,提供全球支付,為進出口市場提供獨特解決方案
Apr 18, 2024 00:43 HKT/SGT
|
|
|
PaySaxas启动,提供全球支付,为进出口市场提供独特解决方案
Apr 18, 2024 00:36 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|